Pharmacokinetics and haemodynamics of ketamine in intensive care patients with brain or spinal cord injury

British Journal of Anaesthesia

Volumn 90, Issue 2, 2003, Pages 155-160

  Hijazi, Y ^a,b   Bodonian, C ^c   Bolon, M ^a,b   Salord, F ^c   Boulieu, R ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b Lab de Pharmacocinetique Clin   (France)

^c HÔPITAL NEUROLOGIQUE   (France)

Author keywords

Brain, injury; Intensive care; Pharmacokinetics, ketamine

Indexed keywords

ANALGESIC AGENT; CIMETIDINE; DRUG METABOLITE; ENZYME INHIBITOR; FLUCONAZOLE; KETAMINE; OMEPRAZOLE; SEDATIVE AGENT;

ADULT; ANESTHESIA INDUCTION; AREA UNDER THE CURVE; ARTICLE; BRAIN INJURY; CLINICAL ARTICLE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; INTENSIVE CARE; MALE; NEUROSURGERY; PATIENT CARE; PRIORITY JOURNAL; SPINAL CORD INJURY; SURGICAL PATIENT; SURGICAL TECHNIQUE; SYSTOLIC BLOOD PRESSURE; VOLUNTEER;

EID: 0037316480     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg028     Document Type: Article

References (27)

1. White PF, Way WL, Trevor AJ. Ketamine - its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-36
2. Nimmo WS, Clements JA. Ketamine on demand for postoperative analgesia. Anaesthesia 1981; 36: 826
3. Kolenda H, Gremmelt A, Rading S, Braun U, Markakis E. Ketamine for analgosedative therapy in intensive care treatment of head-injured patients. Acta Neurochir 1996; 138: 1193-9
4. Marcoux FX, Goodrich JE, Dominick MA. Ketamine prevents ischemic neuronal injury. Brain Res 1988; 452: 329-55
5. Woolf TF, Adams JD. Biotransformation of ketamine, (Z)-6-hydroxyketamine and (E)-6-hydroxyketamine by rat, rabbit and human liver microsomal preparations. Xenobiotica 1987; 17: 839-47
6. Leung LY, Baille T. Comparative pharmacology of ketamine in the rat and its two principal metabolites, norketamine and (Z)-6-hydroxynorketamine. J Med Chem 1986; 24: 2396-9
7. Clements JA, Nimmo WS. Pharmacokinetics and analgesic effects of ketamine in man. Br J Anaesth 1981; 53: 27-30
8. Clements JA, Nimmo WS, Grant IS. Bioavailability, pharmacokinetics, and analgesic activity of ketamine in humans. J Pharm Sci 1982; 71: 539-41
9. Idvall J, Ahlgren I, Aronsen KF, Stenberg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979; 51: 1167-73
10. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereoselective analytical method. Br J Anaesth 1993; 70: 666-71
11. Pietropaoli J, Rogers F, Shackford S, Wadd S. The deleterious effects of intraoperative hypotension on outcome in patients with severe head injury. J Trauma 1993; 33: 403-7
12. Takeshita H, Okuda Y, Sari A. The effects of ketamine on cerebral circulation and metabolism in man. Anesthesiology 1972; 36: 69-74
13. Schwedler M, Miletich DJ, Albrecht RF. Cerebral blood flow and metabolism following ketamine administration. Can Anaesth Soc J 1982; 29: 222-6
14. Pfenninger E, Grunert A, Bowdler I, Kilian J. The effect of ketamine on intracranial pressure during haemorrhagic shock under conditions of both spontaneous breathing and controlled ventilation. Acta Neurochir 1985; 78: 113-18
15. Mayberg TS, Lam AM, Domino KB, Howard M, Win HR. Cerebral blood flow velocity and ADVO2 response to ketamine in neurosurgical patients. Anesthesiology 1993; 79: A204
16. Bolze S, Boulieu R. HPLC determination of ketamine, norketamine and dehydronorketamine in plasma with a high purity reversed phase sorbent. Clin Chem 1998; 44: 560-4
17. Farenc C, Fabreguette JR, Bressolle F. Pk-fit: a pharmacokinetic/pharmacodynamic and statistical data analysis software. Comput Biomed Res 2000; 33: 315-29
18. Malinovsky JM, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after nasal and rectal administration in children. Br J Anaesth 1996; 77: 203-7
19. Hijazi Y, Boulieu R. Contribution of CYP3A4, CYP2C9 and CYP2B6 in N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos 2002; 30: 853-8
20. Kostrubsky VE, Strom SC, Wood SG, Wrighton SA, Sinclair PR. Ethanol and isopentanol increase CYP3A and CYP2E in primary cultures of human hepatocytes. Arch Biochem Biophys 1995; 322: 516-20
21. Ko JW, Sukhova N, Thacker D, Chen P, Flockhart DA. Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 1997; 25: 853-62
22. Honig PK, Worham DC, Zamani K, et al. The effect of fluconazole on the steady state pharmacokinetics and electrocardiographic pharmacodynamics of terfinadine in humans. Clin Pharmacol Ther 1993; 53: 630-6
23. Plaud B, Barre J, Marty J. Altérations pharmacocinétiques chez le malade de réanimation. In: SFAR, ed. 37eme. Congrès National d'Anaesthesie et de Réanimation. Paris: Masson, 1995; 579-92
24. Erny P, Cochard JF. Traumatismes crâniens graves. In: Samii K. Anesthésie Réanimation Chirurgicale. Paris: Flammarion, 1990; 1038-49
25. Miller JD, Dearden NM, Piper IR, et al. Control of intracranial pressure in patients with severe head injury. J Neurotrauma 1992; 9: 317-26
26. Siesjo BK. Basic mechanisms of traumatic brain damage. Ann Emerg Med 1993; 22: 959-69
27. Guengrich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Ann Rev Pharmacol Toxicol 1999; 39: 1-17